This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

CryoCor (CRYO) celebrated another gain, while it was overall a flat-to-down biotech day.

After a rally yesterday tied to a pre-market approval, CryoCor took to gaining again on Friday after announcing a deal with Boston Scientific (BSX - Get Report). The companies will co-develop a console to deliver cryo energy, which uses extreme cold, to Boston Scientific's cryo balloon catheter to treat atrial fibrillation. CryoCor will develop and potentially manufacture the consoles, which will be used with Boston Scientific's internally developed catheter balloons, according to the companies.

Boston Scientific will make payments tied to development milestones, and also sale-based royalties, in addition to purchasing 2.5 million of CryoCor's stock. It will also purchase another $2.5 million tied to development milestones.

CryoCor climbed 84 cents, or 17.5% to $5.65, after rising more than 20% earlier in the day, while Boston Scientific tiptoed in the red 16 cents, or 1%, to $15.34.

Ziopharm (ZIOP - Get Report) presented gene-profiling data and interim phase II trial data for advanced myeloma treatment darinaparsin throughout the week at the Annual Myeloma Workshop in Greece. The company was up 40 cents, or 8.4%, to $5.15.

On the flipside, Antares Pharma (AIS) bled 15 cents, or 8.6%, to $1.60 on Friday after announcing that it will privately place $15 million in newly issued common stock and warrants for additional shares with institutional and other investors. The company said the financing is expected to close after it gets Amex approval.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
CRYO $0.49 -1.80%
ZIOP $9.54 2.00%
BSX $17.31 -0.35%
CYTK $5.72 3.80%
GSK $46.03 0.94%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs